Explore

Rapid Read Rapid Read
FDA-Approved Osteoboost Belt Shows Promise in Reducing Bone Density Loss in Post-Menopausal Women

FDA-Approved Osteoboost Belt Shows Promise in Reducing Bone Density Loss in Post-Menopausal Women

The Osteoboost belt, a device approved by the Food and Drug Administration (FDA) in 2024, is gaining attention for its potential to reduce bone density loss in post-menopausal women with osteopenia. This wearable device delivers low-magnitude vibrations to the spine and hips, mimicking the effects of exercise by stimulating bone-building cells known as osteoblasts. A recent randomized, double-blind, controlled trial involving 126 women aged 50 and older demonstrated that those using the Osteoboost belt experienced significantly less bone strength loss in the spine over a 12-month period compared to a placebo group. The trial reported an 83% reduction in bone strength loss among users of the device. Despite these promising results, some scientists have expressed concerns about the study's conclusions, arguing that the device's localized treatment may not address the systemic nature of osteopenia.
Rapid Read Rapid Read
Amylyx Pharmaceuticals Highlights Post-Bariatric Hypoglycemia Research at ENDO 2026

Amylyx Pharmaceuticals Highlights Post-Bariatric Hypoglycemia Research at ENDO 2026

Amylyx Pharmaceuticals has announced its participation in the Endocrine Society's Annual Meeting (ENDO 2026) with two poster presentations. The presentations focus on post-bariatric hypoglycemia (PBH), a condition affecting individuals who have undergone bariatric surgery. The first presentation examines the healthcare burden and quality of life impacts of PBH in the U.S., while the second discusses the design of the Phase 3 LUCIDITY trial for avexitide, a GLP-1 receptor antagonist being developed to treat PBH. Avexitide has shown promise in reducing hypoglycemic events in clinical trials and has received several FDA designations, including Breakthrough Therapy and Orphan Drug status.
Rapid Read Rapid Read
FDA-Approved Osteoboost Device Shows Promise in Reducing Bone Density Loss in Post-Menopausal Women

FDA-Approved Osteoboost Device Shows Promise in Reducing Bone Density Loss in Post-Menopausal Women

The Osteoboost device, a wearable belt approved by the FDA in 2024, is designed to combat bone density loss in post-menopausal women diagnosed with osteopenia. The device delivers targeted vibrations to the spine and hips, mimicking the effects of exercise by stimulating bone-building cells called osteoblasts. A study involving 126 women over 50 showed that those using the device experienced significantly less bone strength loss in the spine over a year compared to a placebo group. Despite these promising results, some scientists have criticized the study's conclusions, arguing that the device's localized treatment may not be sufficient for a systemic condition like osteopenia. The device is available by prescription and costs about $1,000, as it is not covered by insurance.
Rapid Read Rapid Read
Congressman Meuser Backs Agriculture Funding Bill Benefiting Schuylkill County Courthouse

Congressman Meuser Backs Agriculture Funding Bill Benefiting Schuylkill County Courthouse

Congressman Dan Meuser has expressed his support for the Fiscal Year 2027 Agriculture, Rural Development, Food and Drug Administration (FDA), and Related Agencies Appropriations Act. This spending bill, which narrowly passed the U.S. House of Representatives with a 213-210 vote, includes $1.6 million earmarked for renovations to the Schuylkill County Courthouse in Pottsville. The funding is intended to modernize the courthouse by upgrading elevators, replacing exterior doors and windows, installing new HVAC units, and repairing retaining walls. The bill also supports major federal nutrition programs and allocates significant funds for agricultural research and rural development. The legislation now awaits consideration by the U.S. Senate.
Rapid Read Rapid Read
Self-Directed Care Emerges as Key Model for Long-Term Care in the U.S.

Self-Directed Care Emerges as Key Model for Long-Term Care in the U.S.

Self-directed care is gaining prominence as a sustainable model for long-term care in the United States. Jennifer Truscott, COO of PPL, highlights how this model empowers individuals to choose their caregivers, often family or trusted community members, enhancing care continuity and satisfaction. This approach addresses workforce shortages in traditional home care by expanding the caregiver pool and improving retention. Advances in technology and clearer program rules have facilitated the model's scalability, making it a central pillar in long-term care delivery. The model's success is driven by demographic shifts, consumer preferences, and evidence of improved outcomes.
Trendline Trendline
Stepful Secures $55M to Expand AI-Powered Medical Training Platform

Stepful Secures $55M to Expand AI-Powered Medical Training Platform

Stepful Secures $55M to Expand AI-Powered Medical Training Platform
Trendline Trendline
Eli Lilly's Retatrutide Shows Promising Results in Obesity and Related Conditions

Eli Lilly's Retatrutide Shows Promising Results in Obesity and Related Conditions

Eli Lilly's Retatrutide Shows Promising Results in Obesity and Related Conditions
Rapid Read Rapid Read
Tidepool Unveils New Diabetes Management Data and Women's Health Initiative at ADA 2026

Tidepool Unveils New Diabetes Management Data and Women's Health Initiative at ADA 2026

Tidepool, a nonprofit organization focused on diabetes technology, presented new clinical data and research initiatives at the American Diabetes Association's 86th Scientific Sessions. The presentation highlighted the effectiveness of a 24-week Diabetes Care Management Program (DCMP) in resource-limited settings, which utilized continuous glucose monitoring (CGM) data to improve patient outcomes. The program achieved a 1.59% reduction in HbA1c levels and a 13.4% increase in Time in Range for patients with uncontrolled type 2 diabetes. Additionally, Tidepool announced a landmark initiative aimed at addressing gender equity in diabetes research, focusing on women's health. This initiative seeks to create a large, anonymized dataset of biometric and diabetes device data to better understand and address the unique health challenges faced by women with diabetes.
Discover daily Discover daily
From Multivitamins to Fish Oil: A Guide to Common Supplements

From Multivitamins to Fish Oil: A Guide to Common Supplements

Dietary supplements are a popular choice for many individuals looking to enhance their nutritional intake. These products are designed to provide a...
Trendline Trendline
Corsair Pharma Presents Phase 1 Data for TRX-248 Transdermal System at Pulmonary Hypertension Conference

Corsair Pharma Presents Phase 1 Data for TRX-248 Transdermal System at Pulmonary Hypertension Conference

Corsair Pharma Presents Phase 1 Data for TRX-248 Transdermal System at Pulmonary Hypertension Conference
Trendline Trendline
Drugmakers Shift Focus to Monthly Weight Loss Injections for Enhanced Convenience

Drugmakers Shift Focus to Monthly Weight Loss Injections for Enhanced Convenience

Drugmakers Shift Focus to Monthly Weight Loss Injections for Enhanced Convenience
Trendline Trendline
Amylyx Pharmaceuticals to Present Research on Post-Bariatric Hypoglycemia at ENDO 2026

Amylyx Pharmaceuticals to Present Research on Post-Bariatric Hypoglycemia at ENDO 2026

Amylyx Pharmaceuticals to Present Research on Post-Bariatric Hypoglycemia at ENDO 2026